Audit 353443

FY End
2024-09-30
Total Expended
$4.60M
Findings
0
Programs
18
Year: 2024 Accepted: 2025-04-11
Auditor: Aafcpas INC

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Contacts

Name Title Type
XEUQUDGFNN28 Marian O'Neil Auditee
8573643800 Thomas Muldoon Auditor
No contacts on file

Notes to SEFA

Title: Governmental Interagency Agreement Activities Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards includes the Federal assistance activity of BVARI and is presented on the accrual basis of accounting. The information in this schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. De Minimis Rate Used: N Rate Explanation: BVARI has elected not to use the 10% de minimis cost rate for its Federal programs. As mentioned in Note 9 to the financial statements, BVARI provides services to the VA Boston Healthcare System under a Memorandum of Understanding (MOU). Funding used under this MOU is provided through Interagency Agreements between the National Institute of Health (NIH), the Department of Defense (DoD) or Food and Drug Administration (FDA) and the Department of Veterans Affairs. BVARI provides support to the VA Precision Medicine Initiative Cohort Program (PMI-CP) for administrative, data management, extraction and storage of specimens, as well as health records and survey data, collected from Veterans who enroll into the Precision Medicine Program. BVARI provides support on the “NCI and VA Interagency Group to Accelerate Trials Enrollment” (NAVIGATE) program between NIH and the VA. Spending under the PMI-CP MOU amounted to approximately $5,243,909 for the nine months ended September 30, 2024. Spending under the PMI-CP (DoD) MOU amounted to approximately $53,826 for the nine months ended September 30, 2024. Spending under the NAVIGATE (NIH) MOU amounted to approximately $400,467 for the nine months ended September 30, 2024. Spending under the FDA MOU amounted to approximately $57,544 for the nine months ended September 30, 2024. Although these funds are sourced from the Federal government, they are not considered expenditures of Federal Grant Awards for the purpose of the Schedule of Expenditures of Federal Awards and are therefore not included on that schedule.